Article
JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.
Blood advances - 26 Dec 2023
Rafati Maryam, Brown Derek W, Zhou Weiyin, Jones Kristine, Luo Wen, St Martin Andrew, Wang Youjin, He Meilun, Spellman Stephen R, Wang Tao, Deeg H Joachim, Gupta Vikas, Lee Stephanie J, Bolon Yung-Tsi, Chanock Stephen J, Machiela Mitchell J, Saber Wael, Gadalla Shahinaz M
Abstract excerpt
JAK2 V617F is the most common driver mutation in primary or secondary myelofibrosis for which allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment. Knowledge of the prognostic utility of JAK2 alterations in the HCT setting is limited. We identified all patients with MF who received HCT between 2000 and 2016 and had a pre-HCT blood sample (N = 973) available at the Center of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.